195 related articles for article (PubMed ID: 35708464)
21. Folic acid-conjugated raloxifene hydrochloride carbon nanotube for targeting breast cancer cells.
Jawahar N; De A; Jubee S; Reddy ES
Drug Dev Res; 2020 May; 81(3):305-314. PubMed ID: 31782825
[TBL] [Abstract][Full Text] [Related]
22. Green Nanotechnology in the Formulation of a Novel Solid Dispersed Multilayered Core-Sheath Raloxifene-Loaded Nanofibrous Buccal Film; In Vitro and In Vivo Characterization.
Nageeb El-Helaly S; Abd-Elrasheed E; Salim SA; Fahmy RH; Salah S; El-Ashmoony MM
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33915828
[TBL] [Abstract][Full Text] [Related]
23. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Hosny KM; Bahmdan RH; Alhakamy NA; Alfaleh MA; Ahmed OA; Elkomy MH
J Pharm Sci; 2020 Jul; 109(7):2145-2155. PubMed ID: 32194094
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses.
Guo Z; Afza R; Moneeb Khan M; Khan SU; Khan MW; Ali Z; Batool S; Din FU
Heliyon; 2023 Sep; 9(9):e20107. PubMed ID: 37810010
[TBL] [Abstract][Full Text] [Related]
25. Development, Optimization and Evaluation of 2-Methoxy-Estradiol Loaded Nanocarrier for Prostate Cancer.
Alhakamy NA; Ahmed OA; Fahmy UA; Asfour HZ; Alghaith AF; Mahdi WA; Alshehri S; Md S
Front Pharmacol; 2021; 12():682337. PubMed ID: 34335251
[TBL] [Abstract][Full Text] [Related]
26. Raloxifene and Tamoxifen Reduce PARP Activity, Cytokine and Oxidative Stress Levels in the Brain and Blood of Ovariectomized Rats.
Yazğan B; Yazğan Y; Övey İS; Nazıroğlu M
J Mol Neurosci; 2016 Oct; 60(2):214-22. PubMed ID: 27372663
[TBL] [Abstract][Full Text] [Related]
27. Development of intravaginal rod insert bearing liposomal raloxifene hydrochloride and Leuprolide acetate as a potential carrier for uterine targeting.
Patel A; Dhande R; Thakkar H
J Pharm Pharmacol; 2021 Mar; 73(5):653-663. PubMed ID: 33772288
[TBL] [Abstract][Full Text] [Related]
28. Potentiality of Melittin-Loaded Niosomal Vesicles Against Vancomycin-Intermediate
Sangboonruang S; Semakul N; Obeid MA; Ruano M; Kitidee K; Anukool U; Pringproa K; Chantawannakul P; Ferro VA; Tragoolpua Y; Tragoolpua K
Int J Nanomedicine; 2021; 16():7639-7661. PubMed ID: 34819727
[TBL] [Abstract][Full Text] [Related]
29. Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells.
Qi XY; Liu H; Bi DD; Wang XT; Guo YF; Hao T; Zhang BX; Wang XG; Han MH
Phytomedicine; 2019 Feb; 53():286-293. PubMed ID: 30668409
[TBL] [Abstract][Full Text] [Related]
30. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
[TBL] [Abstract][Full Text] [Related]
31. Design and evaluation of hyaluronic acid-coated PLGA nanoparticles of raloxifene hydrochloride for treatment of breast cancer.
Bhatt K; Patil P; Jani P; Thakkar P; Sawant K
Drug Dev Ind Pharm; 2021 Dec; 47(12):2013-2024. PubMed ID: 35686735
[TBL] [Abstract][Full Text] [Related]
32. Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells.
Mansour GH; El-Magd MA; Mahfouz DH; Abdelhamid IA; Mohamed MF; Ibrahim NS; Hady A Abdel Wahab A; Elzayat EM
Bioorg Chem; 2021 Nov; 116():105329. PubMed ID: 34544028
[TBL] [Abstract][Full Text] [Related]
33. Melittin enhances apoptosis through suppression of IL-6/sIL-6R complex-induced NF-κB and STAT3 activation and Bcl-2 expression for human fibroblast-like synoviocytes in rheumatoid arthritis.
Kim SK; Park KY; Yoon WC; Park SH; Park KK; Yoo DH; Choe JY
Joint Bone Spine; 2011 Oct; 78(5):471-7. PubMed ID: 21354845
[TBL] [Abstract][Full Text] [Related]
34. Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells.
Alhakamy NA; Badr-Eldin SM; Alharbi WS; Alfaleh MA; Al-Hejaili OD; Aldawsari HM; Eid BG; Bakhaidar R; Drago F; Caraci F; Caruso G
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959710
[TBL] [Abstract][Full Text] [Related]
35. Melittin inhibits vascular smooth muscle cell proliferation through induction of apoptosis via suppression of nuclear factor-kappaB and Akt activation and enhancement of apoptotic protein expression.
Son DJ; Ha SJ; Song HS; Lim Y; Yun YP; Lee JW; Moon DC; Park YH; Park BS; Song MJ; Hong JT
J Pharmacol Exp Ther; 2006 May; 317(2):627-34. PubMed ID: 16401728
[TBL] [Abstract][Full Text] [Related]
36. Clinically favorable effects of raloxifene on bone mineral density and serum lipids: population assessment via bivariate analysis.
Shah A; Iversen P; Mitlak B
Prim Care Update Ob Gyns; 1998 Jul; 5(4):165-166. PubMed ID: 10838310
[TBL] [Abstract][Full Text] [Related]
37. Assessing the viability of carbamoylethyl pullulan-g-stearic acid based smart polymeric micelles for tumor targeting of raloxifene.
Sethi S; Bhatia S; Kamboj S; Singh RS; Rana V
Drug Dev Ind Pharm; 2021 Dec; 47(12):1986-1997. PubMed ID: 35645171
[TBL] [Abstract][Full Text] [Related]
38. RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer.
Yadav AS; Radharani NNV; Gorain M; Bulbule A; Shetti D; Roy G; Baby T; Kundu GC
Nanoscale; 2020 May; 12(19):10664-10684. PubMed ID: 32374338
[TBL] [Abstract][Full Text] [Related]
39. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
